[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-ileus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-ileus":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,78,107,135,158,182,205,228,251,275,300,326],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641931","effect-of-liposomal-bupivacaine-tapb-combined-with-oxycodone-pcia-on-postoperative-gastrointestinal-recovery-in-patients-undergoing-major-abdominal-surgery-100641931",false,"NCT07651722","Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Recovery in Patients Undergoing Major Abdominal Surgery","Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Function in Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo elective major abdominal surgery, specifically small bowel or colorectal resections.\n* Aged between 18 and 80 years (inclusive).\n* American Society of Anesthesiologists (ASA) physical status I, II, or III.\n* Capable of understanding the study procedures, cooperating with postoperative pain\u002Frecovery assessments (e.g., VAS, QoR-15, I-FEED), and providing written informed consent prior to surgery.\n\nExclusion Criteria:\n\n* History of significant neuropsychiatric disorders, including schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis, that may interfere with pain perception or cognitive evaluation.\n* History of alcohol abuse or chronic opioid\u002Fanalgesic dependence.\n* Severe, uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg).\n* Severe cardiac, hepatic, renal, or pulmonary dysfunction that poses a high surgical\u002Fanesthetic risk or alters drug metabolism.\n* Pregnant or lactating women.\n* Known allergy, hypersensitivity, or contraindications to any of the study medications, including local anesthetics (ropivacaine, bupivacaine) or opioids (sufentanil, oxycodone).","ALL","18 Years","80 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24],"NA","Rationale and Objective:\n\nThe purpose of this study is to evaluate the clinical efficacy and safety of a novel multimodal analgesia regimen, combining transversus abdominis plane block (TAPB) with patient-controlled intravenous analgesia (PCIA), in improving postoperative gastrointestinal function recovery in patients undergoing major abdominal surgery.\n\nStudy Design and Interventions:\n\nThis is a prospective, single-center, randomized, double-blind, parallel-controlled trial. A total of 132 eligible patients (aged 18-80 years, ASA I-III, scheduled for elective small bowel or colorectal surgery) will be randomly allocated to one of three groups (n = 44 per group) to receive distinct postoperative analgesia regimens:\n\nGroup R-S: 0.375% Ropivacaine TAPB + Sufentanil PCIA; Group LB-S: 266 mg Liposomal Bupivacaine TAPB + Sufentanil PCIA; Group LB-O: 266 mg Liposomal Bupivacaine TAPB + Oxycodone PCIA.\n\nPrimary Outcome:\n\nThe primary outcome is the area under the curve (AUC) of the I-FEED scoring system within the first 7 postoperative days, which comprehensively reflects the overall trajectory of gastrointestinal function recovery.\n\nHypothesis:\n\nThe investigators hypothesize that the combination of long-acting Liposomal Bupivacaine TAPB (for prolonged somatic pain relief) and Oxycodone PCIA (for precise visceral pain control via dual u and k receptor agonism) will synergistically attenuate the perioperative stress-inflammatory response. Consequently, this regimen is expected to significantly mitigate postoperative ileus (POI) and accelerate the recovery of gastrointestinal motility",[27,28],"Postoperative Pain","Postoperative Ileus","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2026-06-16",{"date":37,"type":21},"2026-09",{"name":39,"class":40},"Tianjin First Central Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":41},"100626825","restrictive-vs-liberal-intraoperative-fluid-strategy-and-postoperative-outcomes-after-elective-cesarean-section-100626825","NCT07440667","Restrictive vs Liberal Intraoperative Fluid Strategy and Postoperative Outcomes After Elective Cesarean Section","A Prospective Randomized Controlled Trial Comparing Restrictive and Liberal Intraoperative Fluid Strategies on Postoperative Nausea and Vomiting and Gastrointestinal Recovery After Elective Cesarean Section Under Spinal Anesthesia","Inclusion Criteria:\n\n* Female patients aged 18-45 years\n* ASA physical status II\n* Scheduled for elective cesarean section under spinal anesthesia\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Emergency cesarean section\n* Preeclampsia or eclampsia\n* Known cardiac failure\n* Known renal failure\n* Known hepatic failure\n* Coagulopathy\n* Contraindication to spinal anesthesia\n* Conversion to general anesthesia\n* Major technical complications during spinal anesthesia\n* Refusal to participate","FEMALE","45 Years",{"count":52,"type":21},160,[24],"Spinal anesthesia for elective cesarean section is frequently associated with hemodynamic instability and postoperative complications such as postoperative nausea and vomiting (PONV) and delayed gastrointestinal recovery. Although intraoperative fluid administration is routinely used to prevent spinal-induced hypotension, the optimal fluid strategy remains unclear. Both restrictive and liberal fluid approaches may influence maternal hemodynamics and postoperative outcomes through different physiological mechanisms.\n\nThis prospective, single-center, randomized controlled trial aims to compare restrictive (≤3 mL\u002Fkg\u002Fh) and liberal (\\>3 mL\u002Fkg\u002Fh) intraoperative crystalloid fluid strategies in patients undergoing elective cesarean section under spinal anesthesia. The primary outcome is the incidence of PONV within the first 24 hours postoperatively. Secondary outcomes include postdural puncture headache (PDPH), time to first flatus, hypotension frequency, and vasopressor requirements.",[56,57,58,28,59],"Cesarean Section","Postoperative Nausea and Vomiting (PONV)","Postdural Puncture Headache (PDPH)","Gastrointestinal Recovery",[56,61,62,63,64,65,66,59,67,68],"Spinal Anesthesia","Intraoperative Fluid Therapy","Restrictive Fluid Strategy","Liberal Fluid Strategy","Postoperative Nausea and Vomiting","Postdural Puncture Headache","Hypotension","Vasopressor Use","2026-03-07",{"date":71,"type":33},"2026-03-10",{"date":73,"type":33},"2026-03-04",{"date":75,"type":21},"2027-01-30",{"name":77,"class":40},"Nigde Omer Halisdemir University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100625639","impact-of-chewing-gum-on-postoperative-gut-motility-in-gastrointestinal-surgery-patients-100625639","NCT07425249","Impact of Chewing Gum on Postoperative Gut Motility in Gastrointestinal Surgery Patients","Impact of Chewing Gum on Postoperative Gut Motility in Gastrointestinal Surgery Patients: A Randomized Controlled Trial at Khyber Teaching Hospital, Peshawar, Pakistan","Inclusion Criteria:\n\n* Age between 17 and 85 years.\n* Patients of either gender.\n* Undergoing open gastrointestinal surgical procedures (elective or emergency).\n* Willing to participate and able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with metabolic or endocrine disorders (diabetes mellitus, hypothyroidism, or hyperthyroidism).\n* Patients with renal disease or electrolyte imbalance.\n* Patients with chronic constipation or neuromuscular disorders.\n* Patients with substance abuse or drug addiction.\n* Patients receiving medications affecting gut motility (calcium channel blockers or antiepileptic drugs).\n* Patients with dental prosthesis or undergoing laparoscopic gastrointestinal surgery.","17 Years","85 Years",{"count":88,"type":21},96,[24],"Postoperative ileus (POI) is a frequent complication after abdominal surgery, leading to delayed gastrointestinal motility, prolonged hospital stay, and increased patient discomfort. Chewing gum, as a form of sham feeding, has been proposed to stimulate gut motility through vagal stimulation and increased gastrointestinal secretions. This randomized controlled trial aims to assess the effect of chewing gum on early recovery of gastrointestinal motility in patients undergoing open gastrointestinal surgery.",[28,92,93],"Delayed Gastrointestinal Motility","Postoperative Gut Dysfunction",[28,95,96,97],"Gastrointestinal Motility","Enhanced Recovery After Surgery (ERAS)","Postoperative Recovery","2026-02-16",{"date":100,"type":33},"2026-02-20",{"date":102,"type":33},"2026-01-01",{"date":104,"type":21},"2026-10-29",{"name":106,"class":40},"Khyber Medical University Peshawar",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100624637","phase-4-effect-of-tegileridine-on-postoperative-bowel-function-recovery-in-abdominal-surgery-100624637","NCT07412223","Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery","Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery: A Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Scheduled to undergo elective abdominal surgery under general anesthesia.\n2. Age ≥ 18 years.\n3. Body Mass Index (BMI) between 18 and 30 kg\u002Fm².\n4. American Society of Anesthesiologists (ASA) physical status classification of I to III.\n5. Requires postoperative analgesia and is capable of correctly using a patient-controlled intravenous analgesia (PCIA) pump.\n6. Understands the trial objectives and voluntarily participates, providing written informed consent.\n\nExclusion Criteria:\n\n1. Undergoing gastrointestinal tract surgery.\n2. Has advanced cancer with ascites or extensive metastasis, or is receiving systemic chemotherapy\u002Fradiotherapy, or requires postoperative hyperthermic intraperitoneal chemotherapy (HIPEC).\n3. Diagnosed or suspected gastrointestinal obstruction or emptying disorder.\n4. History of severe cardiovascular or cerebrovascular disease (e.g., severe sinus bradycardia, myocardial infarction, unstable angina, grade II or higher atrioventricular block, history of arrhythmia, NYHA class II or higher heart failure, ischemic stroke) or abnormal QTcF interval at screening ( \\>450 ms for males, \\>470 ms for females).\n5. Comorbid psychiatric or neurological disorders (e.g., schizophrenia, depression, epilepsy) or cognitive dysfunction.\n6. Known allergy to opioid drugs or any component of the trial medications.\n7. Current acute or chronic pain conditions, or presence of hyperalgesia or other sensory disorders.\n8. Long-term opioid therapy (defined as receiving \\>15 mg morphine milligram equivalents per day for more than 3 days per week, over a period exceeding 1 month within the 12 months prior to surgery).\n9. Pregnant or breastfeeding women, or those with a positive pregnancy test at screening or on the day of surgery; or participants (including males) planning for pregnancy.\n10. Significant hepatic or renal dysfunction (e.g., ALT\u002FAST \\> 3 times the upper limit of normal, or requiring renal replacement therapy).\n11. Planned admission to the Intensive Care Unit (ICU) for postoperative management.\n12. Participation in another interventional clinical trial within the 3 months prior to randomization.\n13. Any other condition deemed by the investigator as unsuitable for participation in this trial.",{"count":115,"type":21},152,[117],"PHASE4","Title: Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery: A Multicenter, Randomized, Controlled Trial\n\nThe goal of this clinical trial is to evaluate the effectiveness and safety of tegileridine, a biased μ-opioid receptor agonist, for patient-controlled intravenous analgesia (PCIA) after abdominal surgery.\n\nThe main question it aims to answer is:\n\nIs tegileridine superior to morphine in promoting the recovery of gastrointestinal function within 72 hours after abdominal surgery?\n\nResearchers will compare the experimental group (receiving Fumarate Tegileridine Injection) to the active control group (receiving Morphine Hydrochloride Injection). Both groups will also receive dexmedetomidine in their PCIA pumps. This comparison will determine if tegileridine is more effective for bowel recovery and has a better safety profile.\n\nParticipants who are scheduled for elective abdominal surgery under general anesthesia will:\n\n1. Be randomly assigned to receive either a tegileridine-based or a morphine-based pain relief pump after surgery.\n2. Use the patient-controlled analgesia (PCA) pump for up to 72 hours postoperatively to manage their pain.\n3. Be assessed for the time it takes for their bowel function to return (tolerating food and having gas or bowel movement).\n4. Have their pain levels, overall recovery quality, sleep quality, and any side effects monitored during hospitalization.\n5. Be followed up 30 days after surgery.",[120,28],"Pain, Postoperative",[122,28,27,123,124],"Tegileridine","GI-3 composite endpoint","Abdominal Surgery","NOT_YET_RECRUITING","2026-02-13",{"date":128,"type":33},"2026-02-17",{"date":130,"type":21},"2026-02-24",{"date":132,"type":21},"2027-02-24",{"name":134,"class":40},"Xiangya Hospital of Central South University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100449480","phase-2-use-of-beetroot-juice-to-protect-against-postoperative-ileus-following-colorectal-surgery-beet-it-study-100449480","NCT05133024","Use of Beetroot Juice to Protect Against Postoperative Ileus Following Colorectal Surgery: BEET IT Study","BEET IT","Inclusion Criteria:\n\n* Adult patients undergoing elective colonic and upper rectum laparoscopic surgery requiring an anastomosis, without the need of conversion\n\nExclusion Criteria:\n\nGeneral:\n\n* \\\u003C 18 years of age\n* Pregnancy or breast feeding\n\nMedical:\n\n* Psychiatric pathology capable of affecting comprehension and judgment faculty\n* History of inflammatory bowel disease\n* Chronic vascular disease affecting the intestines\n* Chronic constipation (\\\u003C= 2 bowel movements\u002Fweek)\n* Previous abdominal or pelvic radiation treatment\n* Recent (\\\u003C 3 months before inclusion) or current intra-abdominal infection or inflammation (e.g. diverticulitis, appendicitis, cholecystitis)\n* Use of gut motility influencing agents (e.g. tricyclic antidepressants, chronic use of laxatives)\n* Use of nitrates (e.g. isosorbide dinitrate, nitroglycerin), including daily consumption of beetroot juice (unless stopped for a month prior to the intervention period)\n* Hypotension (\\\u003C 100\u002F60 mmHg)\n* Uncontrolled diabetes mellitus\n* Renal or hepatic insufficiency\n* Known allergies or intolerances to beetroot, nitrates\u002Fnitrites\n* Enrollment in other clinical trials\u002Fexperiments, unless approved by the Ethics Committee(s)\n\nSurgical:\n\n* History of prior colorectal surgery\n* Emergency surgery\n* Open surgery\n* Colorectal surgery not requiring an anastomosis (e.g. colotomy, wedge resection)\n* More than 1 bowel anastomosis planned\n* Concomitant surgical procedures required (e.g. resection of liver or lung metastases)\n* Protective stoma planned",{"count":143,"type":21},170,[145],"PHASE2","The goal of the BEET IT study is to examine if preoperative intake of beetroot juice can ameliorate gastrointestinal (GI) recovery after colorectal surgery and thereby help to reduce the duration of postoperative ileus (POI) and prevent prolonged POI. Adult patients undergoing laparoscopic colorectal surgery are randomized 1:1 to consume either concentrated beetroot juice (active intervention) or nitrate-depleted concentrated beetroot juice (placebo) during the week before their surgery. Blood, tissue and\u002For fecal samples are collected at specific time points pre- and\u002For postoperatively to study markers related to inflammation, oxidative stress and GI function. Patients are followed from the week before surgery (start of the intervention) until 3 months post-surgery. The study takes place at 5 hospitals in Flanders, Belgium.",[28],"2026-02-06",{"date":150,"type":33},"2026-02-10",{"date":152,"type":33},"2021-03-31",{"date":154,"type":21},"2027-12-30",{"name":156,"class":40},"University Hospital, Ghent",6,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":166,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":41},"100464960","phase-2-pyridostigmine-efficacy-and-safety-for-treatment-of-ileus-after-colorectal-surgery-100464960","NCT05334485","Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery","Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery (PESTI Trial)","PESTI","Inclusion Criteria:\n\n1. Adult (age 18 and over) patients with benign or malignant colonic or rectal disease who have undergone elective laparoscopic, robotic, or open colorectal resections with or without ostomy construction at our center, and subsequently developed POI, defined as symptoms of bloating with or without nausea and vomiting, with absence of passage of flatus or stool for at least 48 hours postoperatively and require return to NPO status after initial diet attempts with or without placement of an NGT.\n2. Radiographic confirmation of POI diagnosis either via abdominal radiography (KUB), computed tomography abdomen\u002Fpelvis (CT A\u002FP), or both\n3. ECOG Performance status \\\u003C 4\n4. Laboratory evidence of normal organ function, defined as:\n\n   1. Hemoglobin ≥ 7.0 g\u002FdL\n   2. WBC ≤ 20,000\u002FmcL and ≥ 4,000\u002FmcL\n   3. Platelet count ≥ 100,000\u002FmcL or ≤ 100,000,000\u002FmcL\n   4. AST (SGOT) ≤ 2.5 times the institutional upper limit of normal\n   5. ALT (SGPT) ≤ 2.5 times the institutional upper limit of normal\n   6. Total bilirubin within the upper limit of institutional normal range\n   7. Serum Creatinine within the upper limit of institutional normal range\n\nExclusion Criteria:\n\n1. Radiographic evidence of bowel obstruction\n2. Documented intraabdominal septic complications (IASC, such as abdominopelvic abscess, peritonitis, anastomotic leak) at any time prior to or after enrollment\n3. Isolated small bowel or ostomy surgery without colon or rectal resection\n4. ASA score 5\n5. Pregnant or breastfeeding females as PYR is classified by the FDA as a pregnancy risk category C medication with the potential for teratogenic or abortifacient effects and demonstrated secretion into breastmilk with an unknown but potential risk for adverse effects in the nursing infants\n6. Current use of any other investigational agents including: neostigmine or other acetylcholine esterase inhibitors, alvimopan, metoclopramide, erythromycin, methylnaltrexone, naloxegol, cisapride, and laxatives or cathartics (i.e. milk of magnesia, polyethylene glycol)\n7. History of allergic reactions attributed to PYR or other acetylcholine esterase inhibitors\n8. Patients with any of the following uncontrolled, concurrent illnesses: active or latent MG, bronco-constrictive disease (asthma\u002Freactive airway disease), chronic obstructive lung disease (COPD), symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia including bradycardia, renal failure, hepatic failure, gastroparesis, short bowel syndrome (small bowel \\\u003C 200cm), preexisting short or large bowel dysmotility or pseudo-obstruction, chronic constipation\u002Flaxative use, peritoneal carcinomatosis, and psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",true,{"count":168,"type":21},50,[145,170],"PHASE3","A double blind, placebo controlled, randomized control trial studying the safety and efficacy of pyridostigmine as a rescue therapy for postoperative ileus. Patients who undergo elective colorectal resection with or without creation of an ostomy, and subsequently develop postoperative ileus will be eligible for enrollment. Patients will be randomized to receive either pyridostigmine or placebo in addition to the current elements of standard of care. Patients will also complete the pyridostigmine bromide side effects scale (PBSES) upon enrollment and following each administration of either intervention or placebo to monitor treatment safety and evaluate for the development of side effects.",[28],"2026-01-06",{"date":175,"type":33},"2026-01-07",{"date":177,"type":33},"2024-09-03",{"date":179,"type":21},"2026-10",{"name":181,"class":40},"Stefan Holubar MD MS FACS, FASCRS",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100613844","phase-3-neuromuscular-blocking-agents-on-gastrointestinal-function-following-colorectal-surgery-100613844","NCT07271875","Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery","Effect of Neuromuscular Reversal With Neostigmine\u002FAtropine Versus Sugammadex on Postoperative Gastrointestinal Function Recovery Following Colorectal Surgery","Inclusion Criteria:\n\n* Age ≥ 18 years\n* American Society of Anesthesiologists (ASA) physical status classification I-III\n* Preoperative Mini-Mental State Examination (MMSE) score \\> 23\n* Patients scheduled for elective colorectal surgery under general anesthesia. Disease diagnoses include colorectal cancer, benign polyps, benign strictures, or diverticular disease.\n* Provide informed consent\n\nExclusion Criteria:\n\n* Presence of psychiatric disorders, cognitive impairment, or language communication barriers that may affect assessment compliance.\n* Body Mass Index (BMI) ≥ 35 kg\u002Fm².\n* Severe hepatic dysfunction (Child-Pugh Class C) or renal dysfunction (estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m² and\u002For receiving renal replacement therapy).\n* Pre-existing severe gastrointestinal dysfunction (e.g., intestinal obstruction, active inflammatory bowel disease, severe constipation\u002Fdiarrhea); receipt of neoadjuvant therapy preoperatively; planned stoma creation surgery; or scheduled for low rectal surgery (e.g., low anterior resection, abdominoperineal resection).\n* History of neuromuscular disorders (e.g., myasthenia gravis) or malignant hyperthermia.\n* History of opioid abuse, or chronic non-surgical pain requiring long-term analgesic therapy.\n* Anticipated difficult airway, or patients planned for postoperative transfer to the intensive care unit (ICU) while intubated.\n* Contraindications to the use of neostigmine, atropine, sugammadex, or rocuronium (e.g., known drug allergy, epilepsy, unstable angina, asthma, glaucoma, uncontrolled malignant arrhythmias especially atrioventricular block, severe cardiac valve stenosis); or current use of medications that may significantly influence the effects of neuromuscular blocking agents (e.g., antibiotics such as tetracyclines, aminoglycosides, polymyxins, and clindamycin; antiepileptic drugs; lithium; certain antidepressants such as sertraline and amitriptyline).\n* Pregnant or lactating women.\n* Current participation in other clinical trials that may interfere with the results of this study.","100 Years",{"count":191,"type":21},560,[170],"This study is a clinical research project conducted at Xijing Hospital to compare the effects of two different neuromuscular blockade reversal strategies on the recovery of gastrointestinal (GI) function after colorectal surgery.\n\nMany patients experience slow recovery of bowel function after colorectal surgery, which can lead to discomfort, nausea, vomiting, and a longer hospital stay. This study investigates whether using one medication (sugammadex) to reverse muscle relaxants used during anesthesia leads to better and faster recovery of gastrointestinal function compared to a traditional combination of medications (neostigmine with atropine).\n\nThe study will include 560 adults scheduled for elective colorectal surgery. Participants will be randomly assigned to one of two groups to receive either:\n\nSugammadex (2 mg\u002Fkg), OR Neostigmine (30 μg\u002Fkg) + Atropine (15 μg\u002Fkg) The assigned study drug will be given by intravenous injection at the end of surgery, once measurements show the muscle relaxant is starting to wear off. The patients, surgeons, outcome assessors, and statisticians will be blinded.\n\nThe main goal is to see if more patients in one group recover their gastrointestinal function within 72 hours after surgery. Gastrointestinal recovery is strictly defined as both being able to tolerate food\u002Fdrinks without significant nausea\u002Fvomiting AND having passed gas or had a bowel movement.\n\nThe study will also compare many other important outcomes between the groups, including:\n\n1. Time to first passage of gas, first bowel movement, and first toleration of food.\n2. Pain scores and opioid pain medication use.\n3. Rates of nausea and vomiting.\n4. Overall quality of recovery and patient satisfaction.\n5. Length of hospital stay and total hospitalization costs.\n6. Occurrence of complications within 30 days after surgery.\n7. The safety of both reversal strategies will be closely monitored throughout the study by recording any adverse events.\n\nThis research aims to provide high-quality evidence to help anesthesiologists and surgeons choose the best method to reverse muscle relaxation, potentially leading to faster recovery, fewer complications, and a better overall experience for patients undergoing colorectal surgery.",[195,28,196],"Postoperative Gastrointestinal Dysfunction (POGD)","Colorectal Surgery","2025-11-26",{"date":199,"type":33},"2025-12-09",{"date":102,"type":21},{"date":202,"type":21},"2027-12-31",{"name":204,"class":40},"Xijing Hospital",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100465722","low-pressure-pneumoperitoneum-and-postoperative-ileus-100465722","NCT05344417","Low Pressure Pneumoperitoneum and Postoperative Ileus","Impact of Low Pressure Pneumoperitoneum on Postoperative Ileus and Gastrointestinal Dysfunction in Patients Undergoing Laparoscopic Large Bowel Surgery","Inclusion Criteria:\n\n1. Adult patients \\> 18 years old of both sexes who consent to participate in the study and do not have any of the exclusion criteria.\n2. Patients undergoing laparoscopic right hemicolectomy to remove tumors.\n3. Patients undergoing sigmoid resection to remove polyps, diverticula or tumors.\n\nExclusion Criteria:\n\n1. History of inflammatory bowel disease.\n2. History of intestinal ischemia.\n3. History of intestinal adhesions and adhesive disease.\n4. Patients with a history of bowel resection or major abdominal surgery in the past. Appendectomies and hernia repairs are not considered exclusion criteria.\n5. Patients having epidural catheters placed for postoperative pain control for the study period. Intrathecal morphine injections for postoperative pain control will not exclude the patients from the study.\n6. Significant acid-base and electrolyte imbalance before surgery as determined by the study personnel at the screening stage.\n7. Allergy to or contraindications to rocuronium, or sugammadex.\n8. Patients affected by medical conditions or receiving drugs that may prolong or shorten the duration of rocuronium effect (i.e. aminoglycosides, magnesium).\n9. Significant comorbid conditions as determined by the study personnel at the screening stage.\n10. Patients receiving any drugs that may significantly alter the picture of postoperative ileus (determined by the investigators) will be excluded from the study.\n11. Prisoners and pregnant patients",{"count":213,"type":21},125,[24],"The investigators are testing the hypothesis that lower pressure pneumoperitoneum during laparoscopic large bowel surgery protects the bowel from postoperative ileus and bowel dysfunction leading to faster recovery and discharge from the hospital. Our study will focus on the effects of high or low intraperitoneal pressure as well as pressure variations on the course of postoperative ileus, time to hospital discharge, and postoperative gastrointestinal dysfunction in adult patients undergoing laparoscopic large bowel resection (i.e., sigmoidectomy and right colectomy). A randomized parallel group study will be conducted involving 5 arms of surgical patients to test whether differences on postoperative ileus outcome parameters occur between high (15 mm Hg) and low pressure pneumoperitoneum (8-12 mm Hg), as well as whether there are differences between the 2 insufflation devices that provide constant or variable intrabdominal pressure throughout the laparoscopic surgery. For high pressure pneumoperitoneum, either neostigmine or sugammadex are used for reversal of moderate neuromuscular blockade. For low pressure pneumoperitoneum, sugammadex is used for reversal of deep neuromuscular blockade. The investigators plan to use 2 types of gas insufflation devices, one of which will provide a relatively stable pressure level throughout surgery (AirSeal® device), and the second one will provide a more variable pressure (Olympus standard insufflation device). Using both pressure modalities, the investigators will study the effects of different pressure characteristics on the course of postoperative ileus, duration of in-hospital treatment, pain level, and the stability of hemodynamic and respiratory parameters during surgery. Changes in intrabdominal pressure during the surgery will be monitored and recorded using a custom software for later analysis of fluctuations in pressure to relate them to outcomes. Other parameters will be obtained from EPIC (IHIS) medical charts. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.",[28,217],"Gastrointestinal Dysfunction","2025-10-31",{"date":220,"type":33},"2025-11-03",{"date":222,"type":33},"2024-03-06",{"date":224,"type":21},"2027-07-31",{"name":226,"class":40},"Ohio State University",2,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":41},"100598476","effect-of-thread-embedding-acupuncture-on-postoperative-ileus-recovery-after-colorectal-cancer-surgery-a-multicenter-randomized-controlled-trial-100598476","NCT07071987","Effect of Thread Embedding Acupuncture on Postoperative Ileus Recovery After Colorectal Cancer Surgery: A Multicenter Randomized Controlled Trial","A Multicenter, Randomized Controlled Trial to Evaluate the Efficacy of Thread Embedding Acupuncture in Reducing Postoperative Ileus After Colorectal Cancer Surgery","THREAD-POI","Inclusion Criteria:\n\nAge 18-80 years Diagnosed with stage I-III colorectal cancer Scheduled for elective laparoscopic colorectal resection ASA Physical Status I-III Ability to provide informed consent\n\nExclusion Criteria:\n\nHistory of prior major abdominal surgery Emergency or palliative surgery Combined organ resection or open conversion Severe postoperative complications (e.g., anastomotic leak, GI bleeding) Severe cardiac, hepatic, renal, or psychiatric comorbidities Refusal to undergo acupuncture",{"count":237,"type":21},300,[24],"This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of thread embedding acupuncture (TEA) in promoting gastrointestinal recovery after laparoscopic colorectal cancer surgery. The primary outcome is the time to first flatus. Secondary outcomes include time to first defecation, tolerance to oral intake, length of hospital stay, and patient-reported quality of life.",[241,28,242],"Colorectal Cancer","LARS - Low Anterior Resection Syndrome","2025-07-16",{"date":245,"type":33},"2025-07-18",{"date":247,"type":21},"2025-08-01",{"date":224,"type":21},{"name":250,"class":40},"Northern Jiangsu People's Hospital",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":41},"100594023","simple-bed-exercises-for-reducing-postoperative-ileus-in-colorectal-surgical-patients-100594023","NCT07014046","Simple Bed Exercises for Reducing Postoperative Ileus in Colorectal Surgical Patients.","Simple Bed Exercises for Reducing Postoperative Ileus in Colorectal Surgical Patients, a Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female patients aged \\>\u002F=18 years,\n* patients who are diagnosed with colorectal problems that require elective colorectal surgical intervention either anastomosis or stoma, either open or laparoscopic, and the use of any type of postoperative analgesic,\n* orientate to have informed consent and who have signed informed consent.\n\nExclusion Criteria:\n\n* Patients who are not in the list of elective colorectal surgeries\n* Patients who require intraoperative and long postoperative intensive care \\>1 day,\n* with a history of mental disorder or confusion,\n* patients with any active limitation which affects adherence to the study procedures like severe dementia and physical limitation.",{"count":259,"type":21},76,[24],"The purpose of this study is to examine the effect of simple bed exercises for reducing postoperative ileus among colorectal surgical patients who have completed colorectal surgery and are experiencing postoperative ileus. The research team will recruit participants in list of elective colorectal surgeries from the Department of Surgery in the United Christian Hospital. The potential participants will first be assessed for eligibility by completing a simple screening assessment, which may take 10 minutes at facilities within the United Christian Hospital. If the patients meet the inclusion criteria, they will continue to take part in the study.\n\nThe participants will be assigned randomly (1:1) to either Group 1 or Group 2 via computer randomization. Participants of Group 1 will receive education for simple bed exercises after colorectal surgery. Participants will be asked to have simple bed exercises for 15 minutes, three times a day starting from postoperative day one, until passing the first stool after surgery. All sessions will be conducted by surgical nurse in the United Christian Hospital. Surgical nurses will educate simple bed exercises with exercise video. Participants will be instructed to practise the simple bed exercises 3 times per day for 15 minutes each time at before breakfast, before lunch and before dinner, on top of the standard usual care. Participants in Group 2 will be placed under control group to receive standard usual care.\n\nAll participants are required to record defecation, flatus and tolerance of oral intake starting from postoperative day one. Records will take place at 3-time points for both groups: at breakfast, at lunch and at dinner time. Each time participants must complete one set of record on the logbook provided by nurses. If necessary, clinical records including medical history and follow-up appointment time will be retrieved from electronic medical records.",[28],[264,265],"postoperative ileus","exercise","2025-06-14",{"date":268,"type":33},"2025-06-18",{"date":270,"type":33},"2024-12-01",{"date":272,"type":21},"2025-12-31",{"name":274,"class":40},"The University of Hong Kong",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":281,"targetDuration":283,"studyType":284,"phases":4,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":41},"100590982","implementation-of-an-efferent-loop-stimulation-protocol-prior-to-ileostomy-closure-at-la-paz-university-hospital-100590982","NCT06974500","Implementation of an Efferent Loop Stimulation Protocol Prior to Ileostomy Closure at La Paz University Hospital","IInclusion Criteria:\n\n1. Subjects must be able to understand the purpose and risks of the study, provide informed consent, and authorise the use of confidential health information.\n2. Patients over 18 years of age who, regardless of the underlying cause, have an ileostomy and a medical indication for intestinal transit reconstruction by a general surgeon.\n3. Subjects who are able and willing to participate and to comply with follow-up for the duration of the study.\n\nExclusion Criteria:\n\n1. Subjects with an ileostomy who do not wish to undergo intestinal reconstruction.\n2. Subjects who are unable to complete at least two weeks of efferent loop stimulation prior to reconstruction surgery.\n3. Subjects who do not provide consent to participate in the study.",{"count":282,"type":21},68,"2 Years","OBSERVATIONAL","Stoma creation is a common surgical procedure, employed in certain contexts within general surgery, particularly in colorectal and emergency surgery. Although stoma formation is a life-saving technique, the diversion of intestinal contents has pathophysiological, aesthetic, and psychological repercussions on patients' lives. Stomas may be either permanent or temporary. In temporary cases, a second intervention is required to perform ileostomy closure and restore normal intestinal transit.\n\nSeveral studies indicate that stimulation of the efferent loop prior to ileostomy closure yields benefits in patients' postoperative outcomes. Currently, there is no established protocol for this intervention at Hospital Universitario La Paz. However, implementing such a protocol-given that it is a simple, inexpensive, and accessible intervention-could offer significant cost-effectiveness. It may reduce complications and hospital stay, improve patients' quality of life, and represent a valuable contribution to the General Surgery Departmen",[28,287,288],"Colorectal Cancer Control and Prevention","Stoma - Ileostomy",[290],"Ileostomy , Stoma, Colorectal, Posoperative","2025-05-07",{"date":293,"type":33},"2025-05-16",{"date":295,"type":33},"2025-01-01",{"date":297,"type":21},"2027-04-01",{"name":299,"class":40},"Hospital Universitario La Paz",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":41},"100497040","gastrointestinal-stimulation-as-a-treatment-of-postoperative-ileus-following-extensive-surgery-100497040","NCT05752071","Gastrointestinal Stimulation As a Treatment of Postoperative Ileus Following Extensive Surgery","GaStrointestinal STIMULation As a Treatment of Postoperative IlEus Following Extensive Surgery (STIMULATE). -A Prospective Double-blinded Randomized Controlled Trial","STIMULATE","Inclusion Criteria:\n\n* Patients planned for elective cytoreductive surgery with or without heated intraperitoneal chemotherapy due to either colorectal or appendiceal cancer or with peritoneal metastases or due to pseudomyxoma peritonei\n* Written and orally informed consent\n* Over 18 years of age\n\nExclusion Criteria:\n\n* Previous upper gastric or esophageal resection\n* History of difficulties in swallowing or gastrointestinal stenosis\n* Implanted or portable electrical medical device e.g. cardiac pacemaker, defibrillator or infusion pump etc.\n* Pregnant or breast-feeding women",{"count":309,"type":21},100,[24],"The goal of this clinical trial is to investigate the effect of gastrointestinal stimulation with a pacemaker on the length of postoperative bowel paralysis in patients undergoing major abdominal surgery due to metastasizing colorectal cancer, appendiceal cancer or pseudomyxoma peritonei.\n\nThe main question it aims to answer is if the length of postoperative ileus is reduced when the gastrointestinal tract is stimulated with a pacemaker.\n\nAll participants will undergo cytoreductive surgery +\u002F- heated intraperitoneal chemotherapy (the standard treatment for colorectal cancer, appendiceal cancer with peritoneal carcinomatosis or pseudomyxoma peritonei). After surgery, but before the abdomen is closed a pace lead will be attached to the stomach, exteriorized trough the abdominal wall and connected to an external pacemaker. The pacemaker is either turned on (experimental group) or off (control group).\n\nAfter surgery, patients will be asked to fill out a diary on bowel movements once a day. Once normal bowel function is regained, the pace lead and pacemaker will be removed trough the abdominal wall with a firm pull.",[28,313],"Bowel Paralysis",[315,316],"Stimulation","Postoperative ileus","2025-01-28",{"date":319,"type":33},"2025-01-31",{"date":321,"type":33},"2023-04-01",{"date":323,"type":21},"2027-09",{"name":325,"class":40},"University of Aarhus",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":41},"100489555","phase-1-dexamethasone-in-the-prevention-of-post-spinal-paralytic-ileus-after-cesarean-section-100489555","NCT05654649","Dexamethasone in the Prevention of Post-spinal Paralytic Ileus After Cesarean Section","Dexamethasone in the Prevention of Post-spinal Paralytic Ileus After Cesarean Section, Does it Make a Difference: A Randomized Controlled Study","Inclusion Criteria:\n\n* •All participants will sign an informed consent prior to inclusion in the study.\n\n  * All patients 18-40 years of full-term singleton pregnancy (37-41 weeks).,\n  * American Society of Anaesthesiologists (ASA) classification class I and II scheduled.\n  * for elective or semi-elective surgery (category 3 and 4 Caesarean sections).\n  * All patients under spinal anesthesia for a Single baby pregnancy of more than 32 weeks will be included in this study.\n\nExclusion Criteria:\n\n* will be patients' height \\\u003C 150 or \\> 180 cm.\n* Body mass index (BMI) \\>35 kg m-2.\n* Contraindication or refusal to undergo regional anesthesia.\n* any cardiovascular disease including arrhythmias and severe stenotic valvular heart disease.any renal or hepatic diseased patients.","40 Years",{"count":335,"type":21},90,[337,145],"PHASE1","Postoperative ileus is a perplexing problem for clinical surgeons. It occurs not only after abdominal surgery but also after any surgery that requires general anesthesia. Postoperative ileus is defined as the dysfunction of gastrointestinal motility after surgery, characterized by a decrease in, or stagnation of, intestinal peristalsis.",[28],"2024-11-28",{"date":342,"type":33},"2024-12-02",{"date":344,"type":33},"2022-12-01",{"date":346,"type":21},"2024-12",{"name":348,"class":40},"Assiut University"]